Menu Close

U.S. War on Drugs: The Unwanted Dividends

This is a syndicated repost published with the permission of True Economics. To view original, click here. Opinions herein are not those of the Wall Street Examiner or Lee Adler. Reposting does not imply endorsement. The information presented is for educational or entertainment purposes and is not individual investment advice.

While the U.S. war in Afghanistan drags closer to marking 17th anniversary, and the U.S. war on drugs in Latin America rages into its fourth decade (the U.S. has spent more than 1 trillion dollars since the mid 1970s combating narco-mafias in Latin America), global drugs trade is booming.

According to the data from The Economist, global drugs production has hit a new record high and most of this rise is accounted for by, you’ve guessed it, Afghanistan (for opium) and Latin America (for cocaine):

Source: https://www.economist.com/graphic-detail/2018/06/27/opium-and-cocaine-production-has-reached-record-levels.

For some background on disastrous fallout from the U.S. war on drugs cartels in Latin America, see https://www.theguardian.com/global-development-professionals-network/2014/feb/03/us-war-on-drugs-impact-in-latin-american.

For background on the U.S. policymakers’ surprising inability to learn from their own failures: http://trueeconomics.blogspot.com/2018/05/12518-us-war-in-afghanistan-when.html.

Join the conversation and have a little fun at Capitalstool.com. If you are a new visitor to the Stool, please register and join in! To post your observations and charts, and snide, but good-natured, comments, click here to register. Be sure to respond to the confirmation email which is sent instantly. If not in your inbox, check your spam filter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

RSS
Follow by Email
LinkedIn
Share

Discover more from The Wall Street Examiner

Subscribe now to keep reading and get access to the full archive.

Continue reading